OTSKF - Keros Therapeutics Starts U.S. IPO Effort Amid Market Turmoil
Quick Take
Keros Therapeutics (KROS) has filed to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a clinical stage biopharma developing a pipeline of drug candidates for the treatment of hematological and musculoskeletal disorders.
KROS has a research collaboration with Novo Nordisk for its preclinical metabolic disease candidate.
When we learn more IPO details from management, I’ll provide a final opinion.
Company & Technology
Lexington, Massachusetts-based Keros was founded to develop therapies using a family of proteins called Transforming Growth Factor-Beta,